Jasper Therapeutics Escalates Dose in Hives Trial Following Rapid Complete Responses

Dose Escalation:
Jasper Therapeutics has escalated the dose of briquilimab in its SPOTLIGHT study for chronic inducible urticaria (CIndU) after observing rapid complete responses in the 120mg dose cohort.

Clinical Responses:
14 of 15 participants (93%) in both the 40mg and 120mg dose cohorts achieved a clinical response within the 6-week preliminary analysis period. In the 120mg cohort, 10 of 12 participants (83%) experienced a complete response.

Safety Profile:
Briquilimab was well tolerated, with no serious adverse events and no grade 3 or higher adverse events reported.

Future Plans:
Jasper expects to present full data from the SPOTLIGHT study in the first half of 2025 and plans to report initial data from all cohorts of the BEACON study in CSU during the week of January 6, 2025.

Regulatory Clearance:
The company has obtained regulatory clearance to enroll a 180mg dose cohort in the SPOTLIGHT study, aiming to further evaluate the efficacy and safety of briquilimab at higher doses.

Asthma Study:
Jasper also received Health Canada approval for a Phase 1b/2a asthma challenge study using briquilimab, which will assess its efficacy in treating asthma through mast cell depletion.